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LETTERS TO THE EDITOR
The Art and Science of
Transmyocardial Laser Revascularization
If Jackson Pollack is the artist, then the recent study in JACC by
Saririan and Eisenberg on myocardial laser revascularization is
indeed state of the art. The investigators (1) are to be commended
for attempting to clarify the work that has been done with this
technique, but unfortunately the result is less than satisfactory. To
equate Ho:YAG and CO2 lasers as well as transmyocardial laser
revascularization (TMR) and percutaneous myocardial laser revas-
cularization (PMR) without understanding that vast differences
exist in the laser-tissue interactions and in their ability to treat the
full thickness of the myocardium is analogous to saying that
calcium channel blockers and beta-blockers are of equal impor-
tance postmyocardial infarction because they are both “blockers.”
This lack of discernment is most obvious in the researchers’
discussion of suggested mechanisms of action.
Throughout the discussion, the investigators list a number of
different experiments without identifying what type of laser was
used, what type of model was employed, and whether the model
employed re-creates the clinical scenario. In addition, they ignore
several studies that do clarify the mechanism. These omissions
continue when describing the clinical work. Where significant
differences exist in the clinical trials, the results are lumped
together. In an attempt to tabulate the published series of TMR
patients with 12-month follow-up, the researchers ignored over
220 patients who demonstrated a significant perfusion benefit after
CO2 TMR. The investigators are familiar with these studies, as
they do reference them elsewhere in their report. This perfusion
benefit has also been demonstrated using the same CO2 laser in a
randomized clinical trial. Although this is acknowledged by the
investigators, it is immediately discounted and considered to be a
placebo effect. They claim that a placebo effect can demonstrate an
80% improvement in exertional angina, but this has not been
demonstrated at one year, and certainly it has not been demonstrated
out beyond five years, as has been reported with CO2 TMR.
Moreover, they do not explain how perfusion benefit can be
achieved by placebo. They claim that the patients who crossed over
from medical therapy to TMR in the aforementioned CO2 TMR
trial did so owing to a subjective end point of angina and as a result
of investigator bias. In fact, crossovers occurred after patients
developed unstable angina and were unweanable from intravenous
heparin and nitroglycerin after three attempts to decrease this
maximal medical therapy. This treatment was not controlled by the
investigators and is far from subjective.
Also, comments on the perfusion data from the European CO2
TMR trial are misleading. Although it is true that a decrease
occurred in the number of myocardial segments with reversible
ischemia for patients treated with medical therapy and for TMR,
the decrease in the medical management group was due in part to
a doubling of the fixed defects. No significant increase occurred in
the fixed defects in the TMR group.
To include PMR in this discussion without noting its severe
limitations is inappropriate; for example, regardless of the mech-
anism, a 3- to 4-mm divot created on the subendocardium cannot
be considered to be as complete a treatment as a full thickness
transmural channel. I do agree with the investigators that a review
of the TMR literature suggests that the clinical benefits of PMR
are largely due to the placebo effect. Apparently the U.S. Food and
Drug Administration (FDA) agrees because the FDA recently
deemed Ho:YAG PMR not to be worthy of approval.
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REPLY
We would like to thank Dr. Horvath for his insightful comments.
The goal of our paper was to present an unbiased review of the
topic of myocardial laser revascularization with an emphasis on
randomized, controlled clinical trials. Given the word limitations
imposed on our manuscript, it would have been inappropriate for
us to delve into laser-tissue interactions at the expense of important
clinical data. Moreover, an appropriate reference on laser-tissue
interactions was made available to the reader.
At no point in our paper did we “equate” transmyocardial
revascularization (TMR) and percutaneous myocardial laser revas-
cularization (PMR). These are distinctly separate techniques.
Neither do we suggest that the CO2 and Ho:YAG lasers are of
equal value. Any claim, however, that the CO2 laser is superior to
the Ho:YAG laser is speculative, and remains to be shown in a
head-to-head randomized clinical trial.
The experimental studies quoted in our paper used animal
models of chronic myocardial ischemia, akin to patients with
chronic angina. We found no study that entirely explains the
mechanism of action of TMR. There are several studies for and
against each hypothesis; therein lies the controversy.
We presented the trials in tabular form to emphasize their
similarities. Differences were noted in the text. As Dr. Horvath
points out, a number of small, nonrandomized studies with
short-term follow-up demonstrate enhanced perfusion post-TMR.
This could either be related to laser-induced angiogenesis, or to
the natural development of collateral vessels in patients with
chronic ischemia. The latter explanation emphasizes the danger of
relying on the results of uncontrolled studies because, for the most
part, enhanced perfusion has not been confirmed in randomized
clinical trials. Transmyocardial laser revascularization did not
improve myocardial perfusion in four of five trials in which
perfusion was assessed before and at various times after enrollment.
In the trial by Frazier et al. (1), in which a benefit was seen, there
was only a 49% follow-up in the medical arm of the study. Also,
the degree of symptomatic improvement was vastly disproportion-
ate to the degree of improvement in perfusion.
In the trial by Frazier et al. (1), 59% of patients initially assigned
to maximal medical therapy crossed over to the TMR group. The
investigators allowed crossover as an enticement for patients to
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